Position in MYGN
as of Mar 31, 2026
· filed Apr 28, 2026
Position Value
$394,587
New position
Shares Held
87,686
first reported quarter
Ownership
0.093%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Diagnostics & Research
Healthcare · as of Mar 31, 2026HARBOR CAPITAL ADVISORS, INC. holds $14,635,869 across 10 Diagnostics & Research names. MYGN ranks #9 (2.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RDNT |
RadNet, Inc.
|
105,191 | $5,879,124 | |
| 2 | VCYT |
Veracyte, Inc.
|
58,277 | $1,877,102 | |
| 3 | NEO |
Neogenomics Inc
|
243,617 | $1,807,638 | |
| 4 | TWST |
Twist Bioscience Corp
|
37,399 | $1,777,200 | |
| 5 | DGX |
Quest Diagnostics Inc
|
4,303 | $843,301 | |
| 6 | CSTL |
Castle Biosciences Inc
|
25,614 | $628,823 | |
| 7 | WGS |
GeneDx Holdings Corp.
|
9,220 | $592,108 | |
| 8 | IQV |
Iqvia Holdings Inc.
|
2,824 | $481,604 |
All Filings in MYGN
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $394,587 | 87,686 | Shares | Sole | 2026-04-28 | |
| No filing history on record for this holder in this stock. | ||||||